Palisade Bio Inc (PALI)
6.30
-0.16
(-2.48%)
USD |
NASDAQ |
May 17, 16:00
6.30
0.00 (0.00%)
After-Hours: 20:00
Palisade Bio Cash from Financing (Quarterly): 2.024M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.024M |
| December 31, 2023 | -0.134M |
| September 30, 2023 | 1.571M |
| June 30, 2023 | 5.309M |
| March 31, 2023 | 4.44M |
| December 31, 2022 | 1.714M |
| September 30, 2022 | 12.04M |
| Date | Value |
|---|---|
| June 30, 2022 | 1.586M |
| March 31, 2022 | -0.087M |
| December 31, 2021 | -0.554M |
| September 30, 2021 | 4.545M |
| June 30, 2021 | 19.47M |
| March 31, 2021 | 1.152M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.554M
Minimum
Dec 2021
19.47M
Maximum
Jun 2021
4.083M
Average
1.714M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| TG Therapeutics Inc | 0.01M |
| Protagenic Therapeutics Inc | -- |
| Bio-Path Holdings Inc | 0.514M |
| Jaguar Health Inc | 12.27M |
| Finch Therapeutics Group Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.18M |
| Free Cash Flow | -10.79M |
| Free Cash Flow Per Share (Quarterly) | -4.140 |
| Free Cash Flow Yield | -294.5% |